Learning from case law: Case C-118/24 AG opinion on whether a drug product licensed via the Article 10(i) of Directive 2001/83 abridged licensing procedure can ever be recognised as a generic of a biologic medicinal product

Last updated: 16 June 2026 To view updates, click on the ‘+’ sign below. This post is an attempt to provide salient information on Case C-118/24 concerning EG Labo Laboratoires Eurogenerics SAS and Theramex France SAS vs the French Regulatory…

Read MoreLearning from case law: Case C-118/24 AG opinion on whether a drug product licensed via the Article 10(i) of Directive 2001/83 abridged licensing procedure can ever be recognised as a generic of a biologic medicinal product

FAST-EU, a pilot initiative that enables an accelerated assessment of multinational clinical trials in the European Union

Last updated: 15 June 2026 For updates, click on the ‘+’ sign below. This post aims to provide basic information on the FAST-EU initiative. The information is by no means exhaustive. What is the FAST-Initiative? FAST-EU (Facilitating and Accelerating Strategic…

Read MoreFAST-EU, a pilot initiative that enables an accelerated assessment of multinational clinical trials in the European Union

Learning from Case Law: Case C‑456/24, AG opinion on whether or not a Supplementary Protection certificate (SPC) can be granted for an excipient

This post is an attempt to provide salient information on Case C-456/24 which concerns Halozyme Inc. vs the Supreme Administrative Court, Czech Republic. Specifically, it concerns the events leading up to the CJEU getting involved in the case as well…

Read MoreLearning from Case Law: Case C‑456/24, AG opinion on whether or not a Supplementary Protection certificate (SPC) can be granted for an excipient